Universal Beteiligungs und Servicegesellschaft mbH lessened its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 12.5% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 926,155 shares of the conglomerate's stock after selling 131,726 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.13% of Danaher worth $189,862,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. PFG Advisors grew its stake in shares of Danaher by 40.3% during the first quarter. PFG Advisors now owns 29,714 shares of the conglomerate's stock worth $6,091,000 after purchasing an additional 8,539 shares in the last quarter. Gries Financial LLC raised its holdings in Danaher by 23.8% during the first quarter. Gries Financial LLC now owns 1,317 shares of the conglomerate's stock worth $270,000 after purchasing an additional 253 shares in the last quarter. Sargent Investment Group LLC raised its holdings in Danaher by 14.9% during the first quarter. Sargent Investment Group LLC now owns 16,038 shares of the conglomerate's stock worth $3,288,000 after purchasing an additional 2,080 shares in the last quarter. Lindbrook Capital LLC raised its holdings in Danaher by 6.8% during the first quarter. Lindbrook Capital LLC now owns 5,156 shares of the conglomerate's stock worth $1,057,000 after purchasing an additional 330 shares in the last quarter. Finally, Milestones Administradora de Recursos Ltda. raised its holdings in Danaher by 167.1% during the first quarter. Milestones Administradora de Recursos Ltda. now owns 9,350 shares of the conglomerate's stock worth $1,917,000 after purchasing an additional 5,850 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.
Danaher Trading Up 1.5%
DHR stock traded up $3.04 during midday trading on Friday, reaching $205.85. 2,418,419 shares of the company's stock traded hands, compared to its average volume of 4,250,854. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.05. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $281.70. The business has a 50-day moving average price of $196.19 and a two-hundred day moving average price of $204.15. The company has a market capitalization of $147.32 billion, a P/E ratio of 43.77, a PEG ratio of 2.75 and a beta of 0.77.
Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. During the same quarter last year, the company earned $1.72 earnings per share. Danaher's revenue for the quarter was up 3.4% on a year-over-year basis. Equities research analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.
Danaher Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.62%. Danaher's payout ratio is 27.23%.
Analysts Set New Price Targets
DHR has been the topic of a number of research analyst reports. HSBC cut their price objective on shares of Danaher from $270.00 to $240.00 in a report on Friday, April 25th. Wolfe Research decreased their price objective on Danaher from $275.00 to $220.00 and set an "outperform" rating for the company in a report on Monday, April 7th. Jefferies Financial Group decreased their price objective on Danaher from $260.00 to $230.00 and set a "buy" rating for the company in a report on Tuesday, April 22nd. Deutsche Bank Aktiengesellschaft decreased their price objective on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Finally, UBS Group decreased their target price on shares of Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a research note on Wednesday. Three research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $247.61.
Get Our Latest Research Report on Danaher
Insider Buying and Selling
In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of the company's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the transaction, the chairman directly owned 3,105,808 shares of the company's stock, valued at $611,036,665.92. This represents a 28.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the transaction, the executive vice president owned 15,179 shares of the company's stock, valued at approximately $3,005,442. The trade was a 51.01% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 11.10% of the company's stock.
Danaher Company Profile
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
See Also
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
